or
Bookmark and Share
Anxiolytic composition
   
Document Number
US Patent 4783477
Issued Date
November 8, 1988
Link
Map
Abstract
Medetomidine is useful in the treatment of anxiety disorders.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
3
Comments:
no comments yet
Owner
Farmos-Yhtyma Oy (Turku,FI)
Published
November 8, 1988
Application Number
07/117,876
Filed
November 9, 1987
US Classification
514/396  
Int'l Classification
A61K   31/415   (20060101)  
Priority Data
Nov 11, 1986 [FI] 864570
USPTO Field of Search
514/396  
Related Patents
5438067 - Medetomidine preparations for transdermal administration - Owned by Orion-yhtyma Oy (Espoo,FI)

Salts of medetomidine and optically active enantiomers, thereof, particularly the d-enantiomer are disclosed. These salts may be used to regulate the rate of the transdermal administration of active drugs. The transdermal delivery system comprises a drug impermeable backing layer and an adhesive layer wherein the medetomidine is dispersed throughout the adhesive layer.

5124157 - Method and device for administering dexmedetomidine transdermally - Owned by Cygnus Therapeutic Systems (Redwood City, CA) Farmos Group Ltd. (Turku,FI)

Transdermal administration of dexmedetomidine, the dextrorotatory isomer of medetomidine, is described. The method involves sedating a patient by administering dexmedetomidine to a predetermined area of skin at an administration rate and for a time period effective to achieve the desired level of sedation. A therapeutic system for transdermally administering the drug is also provided. The therapeutic system is in the form of a skin patch which is a laminated composite of a backing layer, an optional anchor adhesive layer, a contact adhesive layer, and one or more additional layers.

5457100 - Method for treatment of recurrent paroxysmal neuropsychiatric

Recurrent paroxysmal neuropsychiatric disorders selected from (1) acute dystonic reactions, (2) seizure disorders and (3) panic disorders may be treated by means of aerosol inhalation of (1) anticholinergic and/or antihistaminic agents, (2) benzodiazepines and (3) antihistaminic agents, respectively.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us